SNCE Stock Price, Science 37 Holdings, . Quote, Chart

Market Summary

USD5.75

Market Closed

SNCE Stock Price

View Fullscreen

SNCE RSI Chart

SNCE Valuation

Market Cap

686.5M

Price/Earnings (Trailing)

-5.51

Price/Sales (Trailing)

11

Price/Free Cashflow

-14.24

SNCE Price/Sales (Trailing)

SNCE Profitability

Return on Equity

-240.9%

Return on Assets

-164.61%

Free Cashflow Yield

-7.02%

SNCE Fundamentals

SNCE Revenue

Revenue (TTM)

62.4M

Rev. Growth (Yr)

-8.38%

Rev. Growth (Qtr)

-3.02%

SNCE Earnings

Earnings (TTM)

-124.7M

Earnings Growth (Yr)

40.82%

Earnings Growth (Qtr)

28.88%

Breaking Down SNCE Revenue

Last 30 days

0.9%

Last 90 days

32.5%

Trailing 12 Months

2446.5%

How does SNCE drawdown profile look like?

SNCE Financial Health

Current Ratio

4.17

SNCE Investor Care

Shares Dilution (1Y)

2.34%

Diluted EPS (TTM)

-1.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	66.8M	62.4M	0
2022	92.1M	98.8M	100.8M	96.4M
2021	32.7M	41.7M	50.6M	59.6M
2020	0	17.3M	20.5M	23.7M
2019	0	0	0	14.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Science 37 Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	cotliar jonathan	back to issuer	-73,968	5.75	-12,864	chief medical officer
Mar 12, 2024	pellizzari christine a	sold	-83,829	5.75	-14,579	chief legal and hr officer
Mar 12, 2024	pellizzari christine a	back to issuer	-201,911	5.75	-35,115	chief legal and hr officer
Mar 12, 2024	von autenried paul	sold	-13,236	5.75	-2,302	-
Mar 12, 2024	hubbard john w	sold	-11,787	5.75	-2,050	-
Mar 12, 2024	rollins emily	sold	-11,787	5.75	-2,050	-
Mar 12, 2024	coman david	sold	-309,546	5.75	-53,834	chief executive officer
Mar 12, 2024	forman darcy	back to issuer	-141,703	5.75	-24,644	chief delivery officer
Mar 12, 2024	zaranek mike	sold	-52,152	5.75	-9,070	chief financial officer
Mar 12, 2024	redmile group, llc	sold	-5,848,920	5.75	-1,017,200	-

Which funds bought or sold SNCE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	sold off	-100	-1,117	-	-%
Apr 15, 2024	KINGSWOOD WEALTH ADVISORS, LLC	sold off	-100	-158,732	-	-%
Apr 02, 2024	M&R CAPITAL MANAGEMENT INC	sold off	-100	-1,869	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-1,291,080	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	856,359	856,359	-%
Feb 14, 2024	Verition Fund Management LLC	new	-	98,331	98,331	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	new	-	471,624	471,624	-%
Feb 14, 2024	Redmile Group, LLC	sold off	-100	-7,923,290	-	-%
Feb 14, 2024	Redmile Group, LLC	new	-	5,288,800	5,288,800	0.19%
Feb 14, 2024	CONTINENTAL ADVISORS LLC	sold off	-100	-178,269	-	-%

Are Funds Buying or Selling SNCE?

Are funds buying SNCE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNCE

No. of Funds

Unveiling Science 37 Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 14, 2024	thermo fisher scientific inc.	0%	0	SC 13D/A
Mar 13, 2024	redmile group, llc	0.0%	0	SC 13D/A
Jan 31, 2024	redmile group, llc	16.5%	994,529	SC 13D/A
Jun 15, 2022	redmile group, llc	17.1%	19,808,234	SC 13D/A
Apr 07, 2022	lux capital management, llc	10.6%	12,249,889	SC 13D/A
Feb 14, 2022	ikarian capital, llc	0.0%	0	SC 13G/A
Feb 14, 2022	rtw investments, lp	3.5%	3,975,000	SC 13G/A

Recent SEC filings of Science 37 Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 25, 2024	15-12G	15-12G
Mar 14, 2024	EFFECT	EFFECT
Mar 14, 2024	EFFECT	EFFECT
Mar 14, 2024	3/A	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	SC 13D/A	13D - Major Acquisition
Mar 13, 2024	SC 13D/A	13D - Major Acquisition
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading

Peers (Alternatives to Science 37 Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	450.9B	371.6B	-1.15%	-0.62%	20.14	1.21	14.64%	11.24%
CI	104.2B	195.3B	-1.86%	40.72%	19.4	0.53	8.17%	-20.79%
CVS	84.9B	357.8B	-15.43%	-7.99%	10.16	0.24	10.95%	93.52%
HCA	82.4B	65.0B	-6.63%	8.38%	15.71	1.27	7.86%	-7.11%
CNC	39.5B	155.5B	-5.93%	7.11%	14.44	0.25	6.34%	84.42%
DVA	12.1B	12.1B	0.07%	52.88%	17.52	1	4.57%	23.40%
UHS	11.7B	14.3B	-7.31%	12.48%	16.33	0.82	6.59%	6.24%
MID-CAP
CHE	8.6B	2.3B	-11.65%	2.88%	30.26	3.74	5.96%	18.29%
ACHC	6.9B	2.9B	-5.81%	3.22%	-317.8	2.35	12.20%	-107.93%
AMN	2.3B	3.8B	-4.85%	-31.12%	10.69	0.59	-27.73%	-52.50%
AMEH	2.1B	1.4B	-9.84%	6.68%	34.56	1.51	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-8.86%	15.22%	24.45	1.44	11.31%	35.83%
BKD	1.3B	3.0B	4.54%	61.07%	-6.92	0.43	6.74%	20.73%
BEAT	54.0M	-	-5.96%	-9.29%	-3.69	-	-	-12.94%
AMS	20.6M	21.3M	10.17%	16.91%	38.6	0.96	8.00%	-62.25%

Science 37 Holdings, Inc. News

Latest updates

Science 37 Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)														(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	-3.0%	14,887,000	15,351,000	15,937,000	16,249,000	19,275,000	44,893,000	20,375,000	14,236,000	12,547,405	10,133,396	7,719,387	5,305,378	2,891,369	-
Costs and Expenses	-17.7%	29,431,000	35,752,000	84,805,500	41,512,000	46,255,000	49,608,000	54,403,000	29,166,000	20,447,000	19,299,000	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	29,165,651	20,447,175	-	23,506,114	14,494,410	9,047,230	-
S&GA Expenses	-11.2%	14,740,000	16,593,000	20,432,500	24,485,000	28,183,000	30,153,000	35,644,500	16,932,000	11,382,000	9,164,000	10,480,397	6,301,712	5,680,480	-
Income Taxes	-	1,000	-	-89,000	-	-	-1,000	1,000	-	-	-	-	-	-	-
Net Income	28.9%	-13,924,000	-19,579,000	-66,521,000	-23,528,000	-5,833,000	44,894,000	-65,098,000	-14,692,000	-7,715,000	-6,826,000	-80,543	-7,683,830	-5,916,947	-
Net Income Margin	-43.3%	-2.00	-1.39	-0.53	-0.49	-0.41	-0.54	-1.58	-0.58	-0.54	-0.63	-0.82	-	-	-
Free Cashflow	96.9%	-404,000	-13,130,000	-15,071,000	-10,026,000	-22,384,000	-28,129,000	-22,316,000	-563,214	-1,387,907	-7,198,000	-4,508,127	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-12.9%	76.00	87.00	101	126	189	210	233	261	40.00	81.00	81.00	57.00	51.00	46.00	40.00
Current Assets	-12.9%	76.00	87.00	101	126	146	169	198	233	19.00	1.00	1.00	46.00	0.00	0.00	33.00
Cash Equivalents	-13.2%	56.00	65.00	83.00	108	130	148	180	215	8.00	19.00	24.00	33.00	48.00	0.00	29.00
Net PPE	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	-	1.00	-	-	1.00
Liabilities	-2.9%	24.00	25.00	23.00	29.00	31.00	34.00	59.00	139	29.00	26.00	23.00	20.00	16.00	12.00	8.00
Current Liabilities	-3.7%	18.00	19.00	17.00	23.00	23.00	26.00	31.00	35.00	25.00	16.00	-	18.00	-	-	6.00
Shareholder's Equity	-16.9%	52.00	62.00	78.00	97.00	159	176	174	122	-	0.00	1.00	1.00	0.00	0.00	-
Retained Earnings	-4.7%	-311	-297	-277	-253	-186	-163	-157	-202	-136	-0.56	-0.19	-107	0.00	0.00	-75.96
Additional Paid-In Capital	1.0%	363	359	356	350	345	339	331	324	1.00	1.00	1.00	2.00	0.00	0.00	1.00
Shares Outstanding	1.7%	119	117	117	116	116	116	115	115	115	7.00	5.00	5.00	-	-	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	96.9%	-400,000	-13,114,000	-19,611,000	-15,066,000	-10,023,000	-22,371,000	-27,983,000	-21,818,000	-215,214	-1,113,907	-7,087,000	-4,400,804	-25,080	-11,236,244	-	-
Share Based Compensation	-0.7%	3,577,000	3,601,000	5,108,000	5,137,000	5,738,000	6,130,000	7,557,000	6,494,000	998,000	690,000	225,000	120,211	105,341	-	-	-
Cashflow From Investing	-74.5%	-7,929,000	-4,544,000	-5,947,000	-7,085,000	-8,402,000	-9,206,000	-7,181,000	-8,504,000	-5,570,000	-2,046,500	-2,409,000	-1,982,535	-1,615,082	-2,568,383	-	-
Cashflow From Financing	-7900.0%	-240,000	-3,000	87,000	-62,000	200,000	358,000	114,000	236,927,000	112,000	535,000	63,000	38,724,741	-108,805	-	25,000	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	15.00	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SNCE Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Revenue	$ 14,887,000	$ 16,249,000	$ 44,324,000	$ 54,210,000
Operating expenses:
Cost of revenue (exclusive of depreciation and amortization)	8,972,000	12,157,000	30,048,000	41,985,000
Selling, general and administrative	14,740,000	24,485,000	51,813,000	82,822,000
Impairment of long-lived assets	5,533,000	0	19,013,000	0
Depreciation and amortization	164,000	4,870,000	520,000	12,569,000
Restructuring costs	22,000	0	3,624,000	0
Total operating expenses	29,431,000	41,512,000	105,018,000	137,376,000
Loss from operations	(14,544,000)	(25,263,000)	(60,694,000)	(83,166,000)
Other income (expense):
Interest income	732,000	559,000	2,475,000	748,000
Sublease income	(2,000)	240,000	64,000	719,000
Change in fair value of earn-out liability	0	1,200,000	110,000	97,600,000
Other income (expense), net	(109,000)	(264,000)	(84,000)	(369,000)
Total other income (expense), net	621,000	1,735,000	2,565,000	98,698,000
Income (loss) before income taxes	(13,923,000)	(23,528,000)	(58,129,000)	15,532,000
Income tax expense (benefit)	1,000	0	1,000	(1,000)
Net income (loss)	$ (13,924,000)	$ (23,528,000)	$ (58,130,000)	$ 15,533,000
(Loss) earnings per share:
Basic (in dollars per share)	$ (0.12)	$ (0.20)	$ (0.50)	$ 0.13
Diluted (in dollars per share)	$ (0.12)	$ (0.20)	$ (0.50)	$ 0.12
Weighted average common shares outstanding:
Basic (in shares)	118,146	116,412	117,210	115,935
Diluted (in shares)	118,146	116,412	117,210	126,717
Comprehensive (loss) income
Net income (loss)	$ (13,924,000)	$ (23,528,000)	$ (58,130,000)	$ 15,533,000
Foreign currency translation	(8,000)	125,000	14,000	152,000
Total comprehensive income (loss)	$ (13,932,000)	$ (23,403,000)	$ (58,116,000)	$ 15,685,000

SNCE Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 56,407	$ 108,091
Accounts receivable and unbilled services, net	12,591	10,992
Prepaid expenses and other current assets	6,543	7,121
Total current assets	75,541	126,204
Other assets	186	244
Total assets	75,727	126,448
Current liabilities:
Accounts payable	6,665	7,206
Accrued expenses and other liabilities	8,355	11,364
Deferred revenue	3,084	4,606
Total current liabilities	18,104	23,176
Non-current liabilities:
Deferred revenue	4,710	3,654
Operating lease liabilities	47	716
Commissions payable	1,062	1,336
Other long-term liabilities	60	180
Total liabilities	23,983	29,062
Commitments and Contingencies (Note 11)
Preferred stock
Preferred stock, $0.0001 par value; 100,000,000 shares authorized, 0 issued and outstanding at September 30, 2023 and December 31, 2022, respectively	0	0
Stockholders’ equity:
Common stock, $0.0001 par value; 400,000,000 shares authorized, 119,118,653 and 116,432,029 issued and outstanding at September 30, 2023 and December 31, 2022, respectively	12	12
Additional paid-in capital	362,755	350,247
Accumulated other comprehensive income	207	193
Accumulated deficit	(311,230)	(253,066)
Total stockholders’ equity	51,744	97,386
Total liabilities, preferred stock and stockholders’ equity	$ 75,727	$ 126,448

About Science 37 Holdings, Inc.

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

CEO	Mr. David Coman
WEBSITE	science37.com
INDUSTRY	Healthcare Plans
EMPLOYEES	460

Science 37 Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Science 37 Holdings, Inc.? What does SNCE stand for in stocks?

SNCE is the stock ticker symbol of Science 37 Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Science 37 Holdings, Inc. (SNCE)?

As of Fri Mar 22 2024, market cap of Science 37 Holdings, Inc. is 686.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNCE stock?

You can check SNCE's fair value in chart for subscribers.

What is the fair value of SNCE stock?

You can check SNCE's fair value in chart for subscribers. The fair value of Science 37 Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Science 37 Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNCE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Science 37 Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNCE is over valued or under valued. Whether Science 37 Holdings, Inc. is cheap or expensive depends on the assumptions which impact Science 37 Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNCE.

What is Science 37 Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 22 2024, SNCE's PE ratio (Price to Earnings) is -5.51 and Price to Sales (PS) ratio is 11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNCE PE ratio will change depending on the future growth rate expectations of investors.